Randomized trial demonstrates irreversible injury from EDC exposure in children, suggesting urgent policy changes.
Endocrine-disrupting chemicals (EDCs) possess abilities to interfere with endogenous hormone action, particularly during the sensitive windows of early development. Consequently linked to a spectrum of pediatric disease, including autism spectrum disorder, ADHD, precocious puberty, obesity, thyroid dysfunction, and atopic disease, EDCs now affect hundreds of millions of children and foretell a growing public health crisis. These outcomes are mechanistically rooted in pediatric-specific toxicokinetic and organizational vulnerabilities. Children accumulate disproportionately higher internal EDC due to elevated intake across multiple routes such as putting objects in their mouths, greater intestinal and dermal bioavailability, and immature detoxification systems that significantly extend the internal half-lives of chemicals, exemplified by a hepatic CYP2E1 expression 12,271-fold lower than that of adults and extending chemical half-lives three to ninefold. While adult responses to EDCs are often transient and activational, early-life EDC exposures are organizational, fundamentally altering physiological architecture through epigenetic reprogramming. Mechanisms include aberrant DNA methylation at imprinted loci, histone modification via MLL1-driven H3K4me3 enrichment, and breach of PI3K/AKT and MAPK/ERK phosphorylation thresholds, producing latent hits manifesting at later hormonal surges. Clinically, disruption of the hypothalamic-pituitary-thyroid axis reduces offspring IQ and elevates ADHD and ASD risk, while PPARγ activation and adipokine dysregulation establish an obesogenic phenotype, and neonatal Th2 immune bias drives selective Th1 apoptosis. This paper synthesizes these biomarkers of pediatric susceptibility to inform tailored biomonitoring strategies, incorporating hair, meconium, and cord blood matrices, and argues for adoption of the precautionary principle in pediatric environmental health policy.
No takes yet. Share an insight, caveat, or question.
Lynn Sung (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: